Literature DB >> 8899849

A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

M Weiss1.   

Abstract

PURPOSE: Flexible parametric models describing the input process after extravascular drug administration are needed for the assessment of absorption rate and the use of population methods in bioavailability and bioequivalence studies.
METHODS: The oral concentration-time curve modeled as the product of the input and disposition function in the Laplace domain was obtained by numerical inversion methods for parameter estimation. The utility of the inverse Gaussian input density was examined using bioavailability data of an extended-release dosage form. Measures of rate of absorption and the cumulative absorbed amount profile were defined in terms of the estimated model parameters.
RESULTS: Accurate estimation of absorption parameters was achieved by simultaneous fitting of the extravascular and intravascular data (describing the latter by a triexponential function). The new input function allowed a direct estimation of both extent of absorption and mean absorption time.
CONCLUSIONS: The findings suggest that the inverse Gaussian density is a useful input function. Its flexibility may reduce the effect of model misspecification in parameter estimation. All parameters can be readily interpreted in terms of the absorption process.

Mesh:

Year:  1996        PMID: 8899849     DOI: 10.1023/a:1016039931663

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.

Authors:  L Endrenyi; S Fritsch; W Yan
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-10

3.  Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. I. Log-convex drug disposition curves.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1986-12

4.  Accuracy of numerical inversion of Laplace transforms for pharmacokinetic parameter estimation.

Authors:  R D Purves
Journal:  J Pharm Sci       Date:  1995-01       Impact factor: 3.534

5.  Bioequivalence: performance of several measures of rate of absorption.

Authors:  F Y Bois; T N Tozer; W W Hauck; M L Chen; R Patnaik; R L Williams
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

6.  In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example.

Authors:  D Brockmeier; H J Dengler; D Voegele
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Assessment of drug absorption after oral administration.

Authors:  K K Chan; M Gibaldi
Journal:  J Pharm Sci       Date:  1985-04       Impact factor: 3.534

8.  Limitations of the maximum entropy principle in devising drug input rate.

Authors:  G Paintaud; L Helleday; C W Maboundou; G Alván
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Bioavailability of controlled release carbamazepine estimated by mixed effect modelling.

Authors:  R Miller; T M Ludden
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate.

Authors:  F Bressolle; R Gomeni; R Alric; M J Royer-Morrot; J Necciari
Journal:  J Pharm Sci       Date:  1994-10       Impact factor: 3.534

View more
  16 in total

1.  Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.

Authors:  A Ring; L Tothfalusi; L Endrenyi; M Weiss
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

2.  Gompertz pharmacokinetic model for drug disposition.

Authors:  Dexter M Easton
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  Application of a gamma model of absorption to oral cyclosporin.

Authors:  J Debord; E Risco; M Harel; Y Le Meur; M Büchler; G Lachâtre; C Le Guellec; P Marquet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

5.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

6.  A note on population analysis of dissolution-absorption models using the inverse Gaussian function.

Authors:  Jian Wang; Michael Weiss; David Z D'Argenio
Journal:  J Clin Pharmacol       Date:  2008-03-21       Impact factor: 3.126

7.  Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model).

Authors:  Jun Shen; Alison Boeckmann; Andrew Vick
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-04       Impact factor: 2.745

8.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

10.  Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.

Authors:  Hee-Doo Yoo; Mi-Suk Kim; Hea-Young Cho; Yong-Bok Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-04-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.